Related references
Note: Only part of the references are listed.Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice
Albrecht Neesse et al.
GUT (2014)
Real-Time Assessment of Tissue Hypoxia In Vivo with Combined Photoacoustics and High-Frequency Ultrasound
Marco Gerling et al.
THERANOSTICS (2014)
3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing
Paola Longati et al.
BMC CANCER (2013)
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Michael A. Jacobetz et al.
GUT (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial
J. M. Loehr et al.
ANNALS OF ONCOLOGY (2012)
Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial
Michele Reni et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells
Shin Hamada et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
EMT and Dissemination Precede Pancreatic Tumor Formation
Andrew D. Rhim et al.
CELL (2012)
Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid
Patrick Michl et al.
GUT (2012)
A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
In Gyu Hwang et al.
INVESTIGATIONAL NEW DRUGS (2012)
Dangerous liaisons: Pancreatic stellate cells and pancreatic cancer cells
Minoti V. Apte et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?
Kian-Huat Lim et al.
ONCOLOGIST (2012)
Cancer Stem Cell Niche: The Place to Be
Tijana Borovski et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Nodal/Activin Signaling Drives Self-Renewal and Tumorigenicity of Pancreatic Cancer Stem Cells and Provides a Target for Combined Drug Therapy
Enza Lonardo et al.
CELL STEM CELL (2011)
Drug Efflux Transporter Multidrug Resistance-Associated Protein 5 Affects Sensitivity of Pancreatic Cancer Cell Lines to the Nucleoside Anticancer Drug 5-Fluorouracil
Praveen K. Nambaru et al.
DRUG METABOLISM AND DISPOSITION (2011)
Stromal biology and therapy in pancreatic cancer
Albrecht Neesse et al.
GUT (2011)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity
David J. Drasin et al.
BREAST CANCER RESEARCH (2011)
Role of Pancreatic Stellate Cells in Pancreatic Cancer Metastasis
Zhihong Xu et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells
Kazuhiro Kikuta et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Pancreatic Cancer
Manuel Hidalgo
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Current Status of Adjuvant Therapy for Pancreatic Cancer
Matthew H. G. Katz et al.
ONCOLOGIST (2010)
Interdependence of Gemcitabine Treatment, Transporter Expression, and Resistance in Human Pancreatic Carcinoma Cells
Wolfgang Hagmann et al.
NEOPLASIA (2010)
Membrane Drug Transporters and Chemoresistance in Human Pancreatic Carcinoma
Wolfgang Hagmann et al.
Cancers (2010)
Epidermal growth factor receptor regulates pancreatic fibrosis
Stacy A. Blaine et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2009)
Down-regulation of αv integrin by retroviral delivery of small interfering RNA reduces multicellular resistance of HT29
Jian-ming He et al.
CANCER LETTERS (2009)
Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance
Yu-Ying Chen et al.
CANCER SCIENCE (2009)
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Piyush B. Gupta et al.
CELL (2009)
Decreased Blood Flow with Increased Metabolic Activity: A Novel Sign of Pancreatic Tumor Aggressiveness
Gaber Komar et al.
CLINICAL CANCER RESEARCH (2009)
ATP-Binding Cassette C Transporters in Human Pancreatic Carcinoma Cell Lines
Wolfgang Hagmann et al.
PANCREATOLOGY (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Environment-mediated drug resistance: a major contributor to minimal residual disease
Mark B. Meads et al.
NATURE REVIEWS CANCER (2009)
Pancreatic stellate cells: Partners in crime with pancreatic cancer cells
Alain Vonlaufen et al.
CANCER RESEARCH (2008)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
Jennifer M. Bailey et al.
CLINICAL CANCER RESEARCH (2008)
A paracrine requirement for hedgehog signalling in cancer
Robert L. Yauch et al.
NATURE (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Utility of contrast-enhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomas
Hiroki Sakamoto et al.
ULTRASOUND IN MEDICINE AND BIOLOGY (2008)
Activin A causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells
Keiji Yoshinaga et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Development and characterization of gemcitabine-resistant pancreatic tumor cells
Ami N. Shah et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Pancreatic cancer microenvironment
Joerg Kleeff et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
Daruka Mahadevan et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Pancreatic stellate cells potentiate proinvasive effects of SERPINE2 expression in pancreatic cancer xenograft tumors
Albrecht Neesse et al.
PANCREATOLOGY (2007)
Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness
Jolanta M. Topczewska et al.
NATURE MEDICINE (2006)
Pancreatic cancer -: From bench to 5-year survival
Joerg Kleeff et al.
PANCREAS (2006)
Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis:: deactivation is induced by matrigel and N-acetylcysteine
R Jesnowski et al.
LABORATORY INVESTIGATION (2005)
Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes
R Grützmann et al.
ONCOGENE (2005)
Risk factors for pancreatic cancer
AB Lowenfels et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Differential diagnosis of pancreatic tumors using ultrasound contrast imaging
A Sofuni et al.
JOURNAL OF GASTROENTEROLOGY (2005)
Trp53R172H and KraSG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
SR Hingorani et al.
CANCER CELL (2005)
Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells
MG Bachem et al.
GASTROENTEROLOGY (2005)
N-cadherin is regulated by activin A and associated with tumor aggressiveness in esophageal carcinoma
K Yoshinaga et al.
CLINICAL CANCER RESEARCH (2004)
Tumor-stroma interaction of human pancreatic cancer: Acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins
H Miyamoto et al.
PANCREAS (2004)
Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma
T Armstrong et al.
CLINICAL CANCER RESEARCH (2004)
Pancreatic cancer stimulates pancreatic stellate cell proliferation and TIMP-1 production through the MAP kinase pathway
S Yoshida et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
SP Thayer et al.
NATURE (2003)
Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death
LA Hazlehurst et al.
ONCOGENE (2003)
Expression of transforming growth factor-β1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis
FWT Shek et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines
G Kouniavsky et al.
CLINICAL & EXPERIMENTAL METASTASIS (2002)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
Multicellular resistance: a paradigm for clinical resistance?
B Desoize et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2000)
Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)
LA Hazlehurst et al.
ONCOGENE (2000)
Share Paper
